Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy

November 6, 2025 Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive Hypertrophic Cardiomyopathy Advances development of ninerafaxstat, a potential first-in-class therapy designed to improve cardiac energetics in patients with serious cardiovascular diseases Enrollment underway across U.S. sites with U.K. and EU expansion anticipated by end of 2025 […] The post Imbria Pharmaceuticals Announces First Patient Randomized in FORTITUDE-HCM Phase 2b Clinical Trial Evaluating Ninerafaxstat for Non-Obstructive